Clinical trial
Open-label, Multicenter, Dose-escalating Phase II Study to Investigate the Safety, Tolerability, and Early Signs of Efficacy of Subcutaneous Administrations of Tadekinig Alfa (IL-18BP) in Patients With Adult -Onset Still's Disease (AoSD) During 12 Weeks
NCT02398435 is registered in ClinicalTrials.gov with AB2 Bio Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-label, Multicenter, Dose-escalating Phase II Study to Investigate the Safety, Tolerability, and Early Signs of Efficacy of Subcutaneous Administrations of Tadekinig Alfa (IL-18BP) in Patients With Adult -Onset Still's Disease (AoSD) During 12 Weeks
- Lead sponsor
- AB2 Bio Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2015
- Completion date
- July 31, 2016
- Enrollment
- 23 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.